title: Thrombogenicity of polysaccharide-coated surfaces.
abstract: Heparinization of artificial surfaces has been proven to reduce the intrinsic thrombogenicity of such surfaces. The mechanism by which immobilized heparin reduces thrombogenicity is not completely understood. In the present study heparin-, alginic acid- and chondroitin-6-sulphate-coated surfaces were examined for protein adsorption, platelet adhesion and thrombin generation. The protein-binding capacity from solutions of purified proteins was significantly higher for heparin-coated surfaces when compared with alginic acid- and chondroitin sulphate-coated surfaces. Yet, when the surfaces were exposed to flowing plasma, only the heparinized surface adsorbed significant amounts of antithrombin. None of the surfaces adsorbed fibrinogen under these conditions, and as a result no platelets adhered from flowing whole blood. Our results indicate that protein adsorption and platelet adhesion from anticoagulated blood cannot be used to assess the thrombogenicity of (coated) artificial surfaces. Indeed, the thrombin generation potentials of the different surfaces varied remarkable: while non-coated surface readily produced thrombin, alginic acid- and chondroitin sulphate-coated surfaces showed a marked reduction and virtually no thrombin was generated in flowing whole blood passing by heparinized surfaces.
authors.affiliation: Department of Biochemistry, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
authors.forename: Jeffrey F W
authors.initials: JF
authors.lastname: Keuren
authors.forename: Simone J H
authors.initials: SJ
authors.lastname: Wielders
authors.forename: George M
authors.initials: GM
authors.lastname: Willems
authors.forename: Marco
authors.initials: M
authors.lastname: Morra
authors.forename: Linda
authors.initials: L
authors.lastname: Cahalan
authors.forename: Patrick
authors.initials: P
authors.lastname: Cahalan
authors.forename: Theo
authors.initials: T
authors.lastname: Lindhout
mesh_terms: D000327:Adsorption; D000464:Alginates / Q000494:pharmacology; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D001798:Blood Proteins / Q000737:chemistry / Q000378:metabolism*; D002809:Chondroitin Sulfates / Q000494:pharmacology; D020099:Coated Materials, Biocompatible / Q000737:chemistry / Q000494:pharmacology*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D020723:Glucuronic Acid; D006493:Heparin / Q000494:pharmacology; D006603:Hexuronic Acids; D006801:Humans; D008422:Materials Testing; D010973:Platelet Adhesiveness / Q000187:drug effects*; D011134:Polysaccharides / Q000494:pharmacology*; D013499:Surface Properties; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000464:Alginates; D000925:Anticoagulants; D001798:Blood Proteins; D020099:Coated Materials, Biocompatible; D005343:Fibrinolytic Agents; D006603:Hexuronic Acids; D011134:Polysaccharides; D020723:Glucuronic Acid; D006493:Heparin; D002809:Chondroitin Sulfates; D013917:Thrombin